Drug Profile
Grepafloxacin - Otsuka Pharmaceuticals
Alternative Names: Grepafloxacin hydrochloride; Grepax; OPC 17116; Raxar; Vaxar; VorzanLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Otsuka Pharmaceutical
- Developer GlaxoSmithKline; Otsuka Pharmaceutical
- Class Antibacterials; Fluoroquinolones; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Market Withdrawal Acute exacerbations of chronic bronchitis; Bacterial infections; Community-acquired pneumonia; Gonococcal urethritis; Gonorrhoea
- Discontinued Respiratory tract infections; Sinusitis; Urinary tract infections
Most Recent Events
- 26 Feb 2008 Discontinued - Clinical-Phase-Unknown for Respiratory tract infections in China (PO)
- 26 Feb 2008 Discontinued - Clinical-Phase-Unknown for Respiratory tract infections in Taiwan (PO)
- 26 Feb 2008 Discontinued - Preregistration for Respiratory tract infections in Japan (PO)